Masters candidate in Biostatistics, Yating Wang, will present:

“Power Analysis for Superiority and Non-inferiority Trials of Ebola Treatments”

Plan B Adviser: Cavan Reilly

Abstract: ZMapp is a promising immune-based treatment for Ebola. A randomized, controlled trial of ZMapp plus the standard of care as compared to the standard of care was conducted. The results showed that the difference between the two treatments was not statistically significant. This might be because of a lack of subjects. There was a new breakout of Ebola in The Democratic Republic of the Congo in August 2018. A randomized trial of three new medicine and ZMapp was designed. In this paper, power analysis of superiority and non-inferiority designs between the new drugs and ZMapp are discussed.

Refreshments will be served prior to the presentation.